Published by Josh White on 9th September 2020
(Sharecast News) - Respiratory drug development company Synairgen updated the market on its intellectual property for the wholly-owned inhaled interferon beta asset 'SNG001' on Wednesday.
URL: http://www.digitallook.com/dl/news/story/31153542/...